Navigation Links
Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
Date:7/22/2008

Study Demonstrates Feasibility and Efficacy of Treating Patients with

Primary Liver Cancer

SAN FRANCISCO, and YONGIN-SI, South Korea, July 22 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), and its South Korean partner Green Cross Corp., announced today that novel findings from a Phase I clinical trial of its first-in-class lead product JX-594 demonstrated that the product was well-tolerated and resulted in clear anti-cancer efficacy in patients with liver cancer. Three patients with advanced treatment-refractory hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) were treated with JX-594. Objective radiographic responses were demonstrated. Serum tumor markers, which correlate with tumor burden over time in patients, decreased by up to 95 percent after treatment. JX-594 replication, its release into the circulation and distant tumor targeting and infection were demonstrated. JX-594 administration resulted in tumor vascular shutdown. Oncolytic virotherapy was also shown, for the first time, to suppress underlying HBV replication in HCC patients by over 50 percent in all three patients. A Phase II clinical trial is now underway for JX-594 in liver cancer. The data were published in the journal Molecular Therapy.

"These clinical results with JX-594 in end-stage liver cancer patients represent a major step forward for JX-594 against this difficult to treat cancer. We are excited by the potential to fulfill the huge unmet medical needs for these desperate patients with no curative treatment options, specifically by treating their tumors and potentially their underlying Hepatitis B viral infection. As a lead site for the on-going Phase II trial of JX-594 for liver cancer, we look forward to extending these results in a larger number of patients," said Dr. Tony Reid, M.D., Ph.D., Associate Professor and Director of Clinical Investigation at the University of California, San Diego Moores
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
2. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
5. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
6. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
7. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
10. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
11. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... and BOSTON , January 23, ... drug discovery and development company, is delighted to announce that ... been awarded to Miles Congreve (Vice President of ... and Malcolm Weir (Chief Executive Officer and co-founder) ...
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
(Date:1/22/2015)... 2015 Increasing sophistication among enterprise buyers of language ... in 2015, says Moravia CMO, Renato ... by market research firm Common Sense Advisory, 15 percent ... translation and localization needs. "From a language industry perspective, ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... NxStage® Medical, Inc. (Nasdaq: NXTM ) ... together with its patients and their care partners is ... and enthusiasm, NxStageUsers, together with thousands of other patients, ... to change the dialysis treatment paradigm and give dialysis ...
... SUNRISE, Fla., Oct. 5, 2011 Actavis Group CEO ... Latin America, among the world,s fastest-growing markets for generic ... at a meeting in South Florida with Actavis, new ... in Sunrise, Florida, will target Brazil, Argentina, Colombia, Mexico, ...
Cached Medicine Technology:NxStage Says 'Thank You' to Patients and Care Partners at the 2nd Annual NxStageUsers Meet-Up and Conference in New Orleans 2NxStage Says 'Thank You' to Patients and Care Partners at the 2nd Annual NxStageUsers Meet-Up and Conference in New Orleans 3Actavis Plans Latin America Expansion 2
(Date:1/22/2015)... Four years since the release of their debut ... the marriage of Avasa & Matthew Love – the duo are ... for release through White Swan Records on February 24, 2015. , ... sacred path available to all of us to walk out of ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for ... its latest collection of wedding dresses , and launches ... is the wedding dress on your big day; the wedding ... Every bride wants to find the most suitable wedding dress. ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining ... for reducing the costs of an auto insurance policy . ... to get lower prices for their vehicle insurance policies. The safety ... determining policy costs. Because of this, drivers should always carry ...
(Date:1/22/2015)... USA (PRWEB) January 22, 2015 State ... statewide data management system with support from GEOSYSTEMS, a ... The new solution will leverage Hexagon Geospatial’s ERDAS ... vector data as well as point clouds and documents. ...
Breaking Medicine News(10 mins):Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... & Johnson,Pharmaceutical Research & Development, L.L.C. announced that ... the U.S. Food and Drug,Administration (FDA) for tapentadol ... for the relief of moderate to,severe acute pain., ... than 25 million,Americans experience acute pain each year ...
... interdisciplinary team reports the design of chimeric ... for potential application in biomedical research. , ... stage where domains that traditionally belonged to ... are coming together to offer new synergistic ...
... made some women opt out of screening mammographies, study finds, ... small as $10 can stand in the way of a ... When women in Medicare managed-care plans were asked to contribute ... 8 percent of the women decided to forgo mammograms altogether, ...
... Procedure brings clot-busting drugs right to site of blood ... -- Therapies that attack blood clots directly in the ... to the standard treatment using clot-busting drugs. , So ... presented Tuesday at the 20th annual International Symposium on ...
... have identified subtle genetic variations that predict the ... found that certain variants in the gene for ... other substances out of the brain compromise the ... and venlafaxine (Effexor). , The researchers said their ...
... Jan. 23 U.S. Environmental,Protection Agency Region 5 has ... Canton, Ohio, for a project to cut diesel emissions ... will be used to retrofit 24 school buses with,equipment ... two 1988,school buses with new, low-emission 2007 model year ...
Cached Medicine News:Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 3Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 4Health News:Engineering chimeric polypeptides to illuminate cellular redox states 2Health News:Co-Pays Contribute to Drop in Preventive Care 2Health News:Co-Pays Contribute to Drop in Preventive Care 3Health News:Advanced Therapy Aids Stroke Patients 2Health News:Advanced Therapy Aids Stroke Patients 3Health News:Genetic difference predicts antidepressant response 2Health News:EPA Awards $154,848 Grant to Canton Local School District for Clean School Bus Project 2
Karlin XL Magnum Cup Curettes, extra long (XL) curettes, black handles, lightweight, length 13 1/4" (33.7 cm), handle length 8 1/2" (21 cm), handle diameter 1 1/4" (32 cm)....
XL Cervical Curette comes with a bayonet design and satin black handles having instrument length 9.5" (24 cm), working distance4.1" (10.4 cm) and handle width 0.6" (1.5 cm)....
Caspar Curette, 250 mm, 10"....
Bone Curette, 160 mm...
Medicine Products: